Liu, Yanfang

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Sonneveld, P., Dimopoulos, M. A., Boccadoro, M., Quach, H., Ho, P. J., Beksac, M., Hulin, C., Antonioli, E., Leleu, X., Mangiacavalli, S., et al. (2024) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 599

Upregulation of autophagy by hypoxia-inducible factor-1α promotes EMT and metastatic ability of CD133+ pancreatic cancer stem-like cells during intermittent hypoxia

ZHU, H., WANG, D., ZHANG, L., XIE, X., WU, Y., LIU, Y., SHAO, G., & SU, Z. (2014) · Oncology Reports

Cancer, Hypoxia, and MetabolismCancer Cells and Metastasis

Cited by 124

IL-17 contributes to cardiac fibrosis following experimental autoimmune myocarditis by a PKCβ/Erk1/2/NF-κB-dependent signaling pathway

Liu, Y., Zhu, H., Su, Z., Sun, C., Yin, J., Yuan, H., Sandoghchian, S., Jiao, Z., Wang, S., & Xu, H. (2012) · International Immunology

Cardiac Fibrosis and RemodelingViral Infections and Immunology Research

Cited by 110

HMGB1 blockade attenuates experimental autoimmune myocarditis and suppresses Th17‐cell expansion

Su, Z., Sun, C., Zhou, C., Liu, Y., Zhu, H., Sandoghchian, S., Zheng, D., Peng, T., Zhang, Y., Jiao, Z., et al. (2011) · European Journal of Immunology

Viral Infections and Immunology ResearchCardiac Fibrosis and Remodeling

Cited by 81

Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).

Srinivasan, R., Donskov, F., Iliopoulos, O., Rathmell, W. K., Narayan, V., Maughan, B. L., Oudard, S., Else, T., Maranchie, J. K., Welsh, S. J., et al. (2021) · Journal of Clinical Oncology

Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

Cited by 22